Exousia Bio, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Exousia Bio shows severe operational deterioration with zero cash, zero revenue (down from $3,750), negative gross margins of $62,108, and accumulated deficit growing to $288,623. Despite a major acquisition valued at $22M creating a gain of $217,922, the company operates with no liquidity and rising liabilities.
Red Flags Detected (7)
Zero cash and cash equivalents on balance sheet
Complete revenue collapse from $3,750 to $0 year-over-year
Negative gross profit of $62,108 with no corresponding revenue
4 more red flags detected
Key Takeaways
Company appears to be in financial distress with no cash and mounting losses
Business model appears broken with costs but no revenue generation
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.